Cerebral Vasospasm (CVS) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026
Cerebral Vasospasm (CVS) Emerging Therapy and TPP Insights Thelansis’s “Cerebral Vasospasm (CVS) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Cerebral Vasospasm (CVS) Overview Cerebral vasospasm (CVS) is a delayed complication following aneurysmal subarachnoid hemorrhage, characterized by pathological macrovascular narrowing driven by subarachnoid blood breakdown products like oxyhemoglobin. Developing 3 to 14 days post-hemorrhage with a peak at day 7, CVS serves as a primary driver of delayed cerebral ischemia (DCI). Patients present with fluctuating focal neurological deficits or altered consciousness. Diagnosis integrates transcranial Doppler showing elevated velocities, CT perfusion, and digital subtraction angiography as the gol...